Camizestrant after surgery for hormone-sensitive early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether adding camizestrant (a hormone-blocking medicine) after breast cancer surgery can lower the chance the cancer returns in ER+/HER2− early breast cancer. It is designed for people who have had definitive local treatment and are being considered for additional “prevention” hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older (any sex) and able to complete study visits
- Have early invasive breast cancer that is ER-positive and HER2-negative, with no signs of spread to other organs
- Have had the main tumor removed with surgery (with or without radiation) and possibly chemotherapy
- Be within 12 months of definitive breast surgery, and you may have taken up to 12 weeks of endocrine (hormone) therapy before joining
- Generally well enough to do daily activities (ECOG 0–1) and have adequate blood, organ, and bone marrow function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
This trial tests if adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can improve outcomes for women with early or locally advanced triple-negative breast cancer. It is for those who haven't had treatment yet and are candidates for surgery.
Hear when a new Breast Cancer, Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.